Appendix 2Characteristics of Included Systematic Reviews and Meta-analyses
View in own window
| Study, Year, Country, Design, and Quality
Assessment Tool, Funding | Electronic searches, and Search Range | Included Studies: Types, Numbers, Publication
Year, Follow-up | Population: Number, conditions | Intervention and Control Groups (No. of
study) | Subgroup or Meta-regression Analysis | Outcomes (No. of study) |
|---|
Chou et al., 2016
9
USA
SR and MA
Risk of Bias developed by the US Preventive Services Task
Force
Agency for Healthcare Research and Quality (AHRQ)
Strength of evidence graded using AHRQ methods
| MEDLINE (Jan 1990 to Oct 2014), Cochrane
Central Register of Controlled Trials and Cochrane Database of
Systematic Reviews (through Sep 2014), ClinicalTrials.gov; restricted to
English language
Updated in Sep 2015 | 14 RCTs
2001 to 2014
Follow-up:
4 weeks to 60 months using fluorescent cystoscopy (3 RCTs) or using
white light cystoscopy (11 RCTs)
Follow-up was for patients with
NMIBC (Ta, Ti and in some cases CIS) on initial cystoscopy: range from 4
weeks to 60 months | 2,906 patients (range 44 to 551
patients)
Mean age: 60 to 74 years
Gender: predominantly
male (ratio not reported)
New bladder cancer (2 RCTs), high risk
bladder cancer (2 RCTs), mixed conditions (10 RCTs) | Intervention: ALA fluorescent light cystoscopy
with TURBT (6 RCTs)
HAL fluorescent light cystoscopy with TURBT
(9 RCTs)
Control: White light cystoscopy with TURBT | By photosensitizing agent |
Mortality (3 RCTs) Harms (3 RCTs)
|
Gakis and Fahmy, 2016
10
Germany and Malaysia
Cochrane risk of bias for RCTs and Newcastle-Ottawa scale for
retrospective studies
Funding: NR
| Pubmed and hand search; restricted to English
language
2000 to 2016 | 4 RCTs and 1 retrospective study
2009
to 2016
Follow-up: 1 to 55 months | 1,301 patients (range 44 to 516)
Mean
age: NR
Patients with NMIBC | HAL fluorescent light cystoscopy with TURBT (5
studies)
Control: White light cystoscopy with TURBT | No |
|
ALA = 5-aminolevulinic acid; CIS = carcinoma in situ; HAL = hexaminolevulinic
acid; MA = meta-analysis; NMIBC = non-muscle invasive bladder cancer; NR =
not reported; RCT = randomized controlled trial; SR = systematic review;
TURBT = transurethral bladder tumor resection; vs = versus
- a
Recurrence: short-term (less than 3 months), intermediate-term (3 months to
less than 1 year), long-term (1 year or more) after initial cystoscopy
- b
Progression to muscle invasive bladder cancer
